Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris.
Douglas WS, Poulin Y, Decroix J, Ortonne JP, Mrowietz U, Gulliver W, Krogstad AL, Larsen FG, Iglesias L, Buckley C, Bibby AJ. Douglas WS, et al. Among authors: poulin y. Acta Derm Venereol. 2002;82(2):131-5. doi: 10.1080/00015550252948194. Acta Derm Venereol. 2002. PMID: 12125943 Free article. Clinical Trial.
A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis: a randomized, double-blind, controlled trial.
Jemec GB, Ganslandt C, Ortonne JP, Poulin Y, Burden AD, de Unamuno P, Berne B, Figueiredo A, Austad J. Jemec GB, et al. Among authors: poulin y. J Am Acad Dermatol. 2008 Sep;59(3):455-63. doi: 10.1016/j.jaad.2008.04.027. J Am Acad Dermatol. 2008. PMID: 18694678 Clinical Trial.
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Paul C, et al. Among authors: poulin y. Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7. Br J Dermatol. 2015. PMID: 26357944 Clinical Trial.
Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.
Blauvelt A, Papp KA, Sofen H, Augustin M, Yosipovitch G, Katoh N, Mrowietz U, Ohtsuki M, Poulin Y, Shrom D, Burge R, See K, Mallbris L, Gordon KB. Blauvelt A, et al. Among authors: poulin y. J Eur Acad Dermatol Venereol. 2017 Jun;31(6):1004-1013. doi: 10.1111/jdv.14163. Epub 2017 Mar 31. J Eur Acad Dermatol Venereol. 2017. PMID: 28190255 Free PMC article. Clinical Trial.
Update on alefacept safety.
Wexler D, Searles G, Landells I, Shear NH, Bissonnette R, Papp K, Poulin Y, Langley R, Gulliver WP. Wexler D, et al. Among authors: poulin y. J Cutan Med Surg. 2009 Dec;13 Suppl 3:S139-47. doi: 10.2310/7750.2009.00032. J Cutan Med Surg. 2009. PMID: 20053326
Ixekizumab Results in Persistent Clinical Improvement in Moderate-to-Severe Genital Psoriasis During a 52 Week, Randomized, Placebo-Controlled, Phase 3 Clinical Trial.
Guenther L, Potts Bleakman A, Weisman J, Poulin Y, Spelman L, Burge R, Erickson J, Todd K, Bertram CC, Ryan C. Guenther L, et al. Among authors: poulin y. Acta Derm Venereol. 2020 Jan 7;100(1):adv00006. doi: 10.2340/00015555-3353. Acta Derm Venereol. 2020. PMID: 31620802 Free PMC article. Clinical Trial.
The use of alefacept in the treatment of psoriasis.
Langley R, Gupta AK, Poulin Y, Guenther L, Barber K, Gulliver W, Lynde C. Langley R, et al. Among authors: poulin y. J Cutan Med Surg. 2004 Aug;8 Suppl:14-8. doi: 10.1007/s10227-004-2004-5. J Cutan Med Surg. 2004. PMID: 15655585 Review. No abstract available.
184 results